KLENIL UDV SUSPENSION FOR INHALATION 0.8 MG AMPOULE 2 ML

Release form

Suspension for inhalation.

Packaging

In a strip of 5 plastic vials of 2 ml. In carton pack 4 stripe.

Mechanism of action

Klenil UDV has anti-inflammatory and antiallergic effect. It inhibits the release of inflammatory mediators, increases the production of lipomodulin - an inhibitor of phospholipase A, reduces the release of arachidonic acid, inhibits the synthesis of prostaglandins. Warns neutrophil regional accumulation, reducing the formation of inflammatory exudate and production of lymphokines, inhibits the migration of macrophages, which leads to slower processes of infiltration and granulation.

Increases the number of active a-adrenergic receptors, neutralizes their desensitization, restores the patient's response to bronchodilators, allowing to reduce the frequency of their use.

Under the action of beclomethasone, the number of fat cells in the bronchial mucosa decreases, and the epithelium edema and secretion of mucus by the bronchial glands are reduced. It causes relaxation of the smooth muscles of the bronchi, reduces their hyperreactivity and improves the performance of external respiration function. Does not possess mineralocorticoid activity. In therapeutic doses does not cause side effects characteristic of systemic corticosteroids. With intranasal use eliminates swelling, hyperemia of the nasal mucosa. The therapeutic effect usually develops after 5-7 days of course application of beclomethasone. When used topically and locally, it has anti-allergic and anti-inflammatory effects.

Indications

For inhalation use: treatment of bronchial asthma (including with insufficient effectiveness of bronchodilators and / or sodium cromoglycate, as well as hormone-dependent severe bronchial asthma in adults and children).

For intranasal use: prevention and treatment of year-round and seasonal allergic rhinitis, including rhinitis with hay fever, vasomotor rhinitis.

For external and local use: in combination with antimicrobial agents - infectious and inflammatory diseases of the skin and ear.

Contraindications

- Severe bouts of bronchial asthma requiring intensive care.
- Tuberculosis.
- Candidomycosis of the upper respiratory tract.
- I trimester of pregnancy.
- Increased sensitivity to beclomethasone.

Use during pregnancy and lactation

Application in the II and III trimesters of pregnancy is possible only in the case when the intended benefits to the mother outweigh the potential risk to the fetus. Newborns whose mothers received beclomethasone during pregnancy should be carefully examined for lack of adrenal function.

If necessary, use during lactation should decide on the termination of breastfeeding.

Special notes

Beclomethasone is not intended to relieve acute asthma attacks. It also should not be used for severe attacks of asthma that require intensive care. The recommended route of administration for the dosage form used should be strictly followed.

With extreme caution and under the close supervision of a physician, beclomethasone should be used in patients with adrenal insufficiency.

The transfer of patients who constantly take GCS by mouth into inhalation forms can be made only in a stable condition.

In the case of the likelihood of the development of paradoxical bronchospasm 10-15 minutes prior to the administration of beclomethasone, inhalation of bronchodilators (for example, salbutamol) is carried out.

With the development of candidiasis of the oral cavity and upper respiratory tract, local antifungal therapy is shown without discontinuing treatment with beclomethasone. Infectious-inflammatory diseases of the nasal cavity and paranasal sinuses in the appointment of appropriate therapy are not a contraindication for treatment with beclomethasone.

Preparations for inhalation use, containing in a dose of 250 mg of beclomethasone, are not intended for children under the age of 12 years.

Composition

1 ampoule contains: beclomethasone dipropionate 800 mcg.

Excipients: polysorbate 20, sorbitan laurate, sodium chloride, purified water.

Dosage and administration

For adults with inhalation, the average dose is 400 mg / day., The frequency of use is 2-4 times / day. If necessary, the dose can be increased to 1 g / day.
For children, a single dose - 50-100 mg, the frequency of use - 2-4 times / day.

With intranasal administration, the dose is 400 mcg / day, the frequency of application is 1-4 times / day.

With external and local application, the dose depends on the indications and the dosage form used.

Drug interaction

With simultaneous use of beclomethasone with other corticosteroids for systemic or intranasal use, it is possible to enhance the suppression of the function of the adrenal cortex.

Prior inhalation use of beta-adrenostimulyatorov can increase the clinical efficacy of beclomethasone.